Skip to content
OpenCapital
Get started

Castle Biosciences CSTL Cash & Equivalents

Cash & Equivalents at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$981.1M+166%
Veracyte logo
VeracyteVCYT
$264.79M+41.0%
Personalis, Inc. logo
Personalis, Inc.PSNL
$73.59M+3.7%
NeoGenomics logo
NeoGenomicsNEO
$146.14M-57.8%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
$23.4M-65.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$241.21M+91.4%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S2×+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's cash & equivalents?
Castle Biosciences (CSTL) reported cash & equivalents of $63.76M in Q1 2026.
How has Castle Biosciences's cash & equivalents changed year-over-year?
Castle Biosciences's cash & equivalents decreased by 28.9% year-over-year, from $89.69M to $63.76M.
What is the long-term trend for Castle Biosciences's cash & equivalents?
Over 5 years (2020 to 2025), Castle Biosciences's cash & equivalents has grown at a -22.2% compound annual growth rate (CAGR), from $409.85M to $116.73M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.